Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Change in Receivables (2016 - 2025)

Ligand Pharmaceuticals' Change in Receivables history spans 16 years, with the latest figure at $2.1 million for Q4 2025.

  • For Q4 2025, Change in Receivables fell 63.16% year-over-year to $2.1 million; the TTM value through Dec 2025 reached $21.7 million, up 236.54%, while the annual FY2025 figure was $21.7 million, 236.54% up from the prior year.
  • Change in Receivables for Q4 2025 was $2.1 million at Ligand Pharmaceuticals, down from $16.3 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $20.4 million in Q2 2022 and bottomed at -$43.6 million in Q1 2022.
  • The 5-year median for Change in Receivables is $2.4 million (2022), against an average of $204700.0.
  • The largest annual shift saw Change in Receivables plummeted 1709.95% in 2022 before it skyrocketed 757.15% in 2024.
  • A 5-year view of Change in Receivables shows it stood at $19.8 million in 2021, then crashed by 275.8% to -$34.8 million in 2022, then surged by 91.85% to -$2.8 million in 2023, then surged by 299.82% to $5.7 million in 2024, then crashed by 63.16% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Change in Receivables are $2.1 million (Q4 2025), $16.3 million (Q3 2025), and $2.8 million (Q2 2025).